181 related articles for article (PubMed ID: 9490144)
1. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Abbou CC; Lucas C; Leblanc V
Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
Zerbib M; Lucas C; Leblanc V
Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
6. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
9. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
11. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
[TBL] [Abstract][Full Text] [Related]
13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
14. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
15. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer.
Kao CC; Chang YH; Wu T; Sun GH; Yu DS; Chang SY; Cha TL
J Chin Med Assoc; 2012 Jun; 75(6):255-61. PubMed ID: 22721619
[TBL] [Abstract][Full Text] [Related]
16. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
[TBL] [Abstract][Full Text] [Related]
17. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
[TBL] [Abstract][Full Text] [Related]
19. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
Lundström EA; Rencken RK; van Wyk JH; Coetzee LJ; Bahlmann JC; Reif S; Strasheim EA; Bigalke MC; Pontin AR; Goedhals L; Steyn DG; Heyns CF; Aldera LA; Mackenzie TM; Purcea D; Grosgurin PY; Porchet HC
Clin Drug Investig; 2009; 29(12):757-65. PubMed ID: 19888782
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen-all that rises is not refractory.
Hintz BL; Van Nieuwenhuize A; Kagan AR
Urology; 2001 May; 57(5):975. PubMed ID: 11337308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
